72 results about "Rupatadine" patented technology

The invention discloses a compound rupatadine bioadhesion nasal gel product and a preparation method. The compound rupatadine bioadhesion nasal gel product is characterized by being prepared from, 10-100 parts of rupatadine and salts thereof, 5-20 parts of xylometazoline hydrochloride / naphazoline / pseudoephedrine hydrochloride, 1-4 parts of furacilin, 300-5000 parts of polymer gel materials, 2-200 parts of a biological adhesive, 180-200 parts of a buffer salt, 800-1600 parts of a wetting agent and 20000 parts of sterile water for injection. The wetting agent is dissolved into 2 / 3 of the sterile water for injection to obtain a solution A; the polymer gel material is stirred and added into the solution A to obtain a gel system B; the biological adhesive is dispersed into the gel system B to obtain a gel system C; the rupatadine and salts thereof, the xylometazoline hydrochloride / naphazoline / pseudoephedrine hydrochloride, the furacilin and the buffer salt are successively added into 1 / 3 of the sterile water for injection, and sonication is performed to obtain a solution D; the solution D is dispersed into the gel system C, and stirring is performed to obtain the final product.

The invention provides a rupatadine fumarate compound which has dual effects of antihistamine and antagonistic platelet activating factor (PAF). According to the research, allergy and inflammatory diseases are multi-factor complex processes caused by generation and release of various different media; histamine is the most inflammatory medium appearing in allergy early symptom, and the disease symptoms including sneezing, rhinocnesmus, tearing, running nose, skin itch, wheal and the like are mostly caused by histamine H1 receptor. And PAF also can cause bronchial constriction and increased permeability of the vessel, so that running nose, nasal congestion, wheal and itch are caused; meanwhile, the PAF is also a main cause of asthma. The antiallergic drug which is clinically used only has an antihistamine activity effect, but does not have a PAF antagonistic effect.

The invention discloses novel use of rupatadine for preventing or treating pulmonary fibrosis. The rupatadine is remarkable in curative effect for treating the pulmonary fibrosis, little toxic and side effect and safe in use.